Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial

Conclusions:
IGF-I inhibition by pasireotide, acting through the IGF-1R, was associated with decreased proliferation and increased apoptosis in pre-malignant breast lesions and one DCIS. Assuming hyperglycemia can be controlled, these data suggest that inhibiting the IGF-I pathway may prove an effective alternative for breast cancer chemoprevention.Trial registrationNCT01372644 Trial date: July 1, 2007.

Source: Breast Cancer Research - November 11, 2014 Category: Cancer & Oncology Authors: Baljit SinghJulia SmithDeborah AxelrodPietro AmeriHeather LevittAnn DanoffMartin LesserCristina de AngelisIrineu Illa-BochacaSara LubitzDaniel HubermanFarbod DarvishianDavid Kleinberg Source Type: research